IFPMA Influenza Vaccine Supply International Task Force Welcomes Sinovac and PowderMed as its Latest Members
Geneva, 5/14/2007 - Geneva, 14 May 2007 – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announces that the IFPMA Influenza Vaccine Supply (IVS) international task force has admitted Sinovac Biotech Ltd. and PowderMed Ltd. as members. Both companies satisfy IVS membership criteria; conducting innovative influenza vaccine research, practicing robust intellectual property protection and complying with GMP (Good Manufacturing Practice).
Dr. Harvey Bale, Director General of the IFPMA, said: “The IFPMA IVS seeks to be as broadly representative as possible and is keen to welcome all research-based influenza vaccine manufacturers. Sinovac, the first Chinese company to join the IFPMA family, is confirmation of China’s move to become a force in research-based health care. PowderMed is opening up a new field of innovation, working on DNA-based vaccines which promise to be easier to produce, deliver and administer than conventional vaccines. This and other new technologies being worked on by other IVS members could help the industry to protect more people in the event of an influenza pandemic.”
Sinovac focuses on the research, development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for new health threats such as SARS and avian influenza. Its headquarters and R&D facility are located in the Beijing University Biological Industry Park, and it is the only Chinese vaccine company listed on an American Stock Exchange. Sinovac's partners include the Chinese National Institutes for Animal Science, Infectious Disease Control, and Viral Disease Control and Prevention.
PowderMed is a UK-based company focused on the development and manufacture of DNA-based vaccines for viral diseases and cancer. DNA vaccines offer the potential of faster manufacturing and should not need a refrigerated supply chain. PowderMed vaccines are delivered using a virtually painless needle-free delivery system that requires minimal medical training and allows self-administration.